Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
about
Blind prediction of HIV integrase binding from the SAMPL4 challengeResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsDolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kineticsExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesHIV-1 drug resistance and resistance testing.Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutationsDesign, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.The emergence of drug resistant HIV variants and novel anti-retroviral therapy.Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.Drug resistant integrase mutants cause aberrant HIV integrations.Dolutegravir: first global approval.Dolutegravir: an exciting new kid on the block.Integrase strand transfer inhibitors in the management of HIV-positive individuals.Elvitegravir: a review of its use in adults with HIV-1 infection.Will drug resistance against dolutegravir in initial therapy ever occur?Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.HIV-1 resistance to dolutegravir: update and new insights.HIV drug resistance against strand transfer integrase inhibitors2014 Update of the drug resistance mutations in HIV-1Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase
P2860
Q26864619-3ED68794-98AC-440D-85ED-AD69D779E713Q28533830-9DD24031-9051-42CA-8708-681F7474EB7CQ28534464-A9B56029-572E-4CDC-AF6E-98986601E0E3Q28540200-DD018028-BC71-4296-9F72-00078AE34395Q30245693-6E10F4F7-E9E6-4282-A921-622B5DB3FA1AQ33680234-57991FFB-2F07-43BB-9945-FBE80972C8DBQ33963458-D4E120F0-17C0-430B-8294-292F332DD20AQ34059119-8B44EEB0-C7A7-44CD-AEDE-555231CC2781Q34059575-6737C64F-DFFE-48F9-99A8-2D75774023F9Q34976284-1EC8D61D-C3A0-49D5-858F-771530B5989FQ35083423-3102BE29-79D3-4095-8B37-62E6CFA6DEA5Q35134947-D4AA2FD3-01E2-4249-85B4-240D1B08F4D5Q35540399-236B4776-DAF2-4089-A97E-3EBA92A67093Q35607763-11578487-9E91-4ED4-9DEC-08E1AEF46E00Q36146699-80D6ECBF-39EB-4E94-9FFE-0B0B9BBD9B29Q36281109-657B358C-778F-491B-8AA4-8DDEC6EBD459Q36284159-E2DF3F20-C11A-445D-B091-A41B9D73B54CQ36571812-0CC24E76-7065-4941-855A-9A675DF17ADEQ36963496-C1ACFB79-CC6B-41E8-8C11-0D8F38C20537Q37124155-6F6B4BB5-90A0-4DFE-B1E2-1F96E3EF3B68Q37294690-95AF00DF-6B59-449A-AD90-3FA4210EA2C5Q38139885-C39574B6-4A41-4A8E-A059-1DE8BC9AB4C1Q38180458-B7A46C99-3BBF-41B1-A9EF-0800D420A29FQ38192022-0E573B5E-3F20-45A7-8E07-DB818AC4FFD2Q38199659-7DDE9CD3-CD7A-4DF3-BA02-8F72CA6906E9Q38478832-BE212115-CC50-4C47-B878-6750DA0B9196Q38570500-CECE486F-94B2-4E1B-8734-5F0D15020AE2Q38601891-05753EC3-65C1-484A-82C1-0D9243E99DF6Q38915885-F9FE8F90-8B7F-4AEB-BE7A-60E46E5F8A1CQ39352571-42B45015-37C6-440D-924F-8B7EE4926E77Q39498339-E96BD61E-D1E9-4E83-8353-D956B35913B7Q39566226-A2D640DF-DA3B-4EEC-BF4C-942A372B5462Q40404531-C79CF74D-8C21-43F4-9956-C8D1D983A49DQ40655736-E8AC605A-A0A8-4F62-9BBE-A427498C3C55Q41141601-DA958B3C-9A48-44CC-AA1B-82FEA2C83AFBQ41412021-27AB785E-8E81-441A-96F7-202C5418F99CQ41686477-5B0EB9BF-86BF-4910-9420-49BF25931EA9Q41935102-3DDB6271-DB69-47FC-A2C5-593582643BCFQ47301806-89C97A3E-6139-4A65-9513-3E7E56FAE373Q58760446-147486EA-8B7B-4854-BA73-BAE5873054D7
P2860
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of primary elvitegravir ...... and viral replication fitness
@en
Impact of primary elvitegravir ...... and viral replication fitness.
@nl
type
label
Impact of primary elvitegravir ...... and viral replication fitness
@en
Impact of primary elvitegravir ...... and viral replication fitness.
@nl
prefLabel
Impact of primary elvitegravir ...... and viral replication fitness
@en
Impact of primary elvitegravir ...... and viral replication fitness.
@nl
P2093
P2860
P356
P1476
Impact of primary elvitegravir ...... and viral replication fitness
@en
P2093
Anita Niedziela-Majka
Damian J McColl
Derrick D Goodman
Evguenia S Svarovskaia
Kirsten L White
Kristen N Andreatta
Michael D Miller
Michael E Abram
Nicolas A Margot
Nikolai Novikov
P2860
P304
P356
10.1128/AAC.02568-12
P407
P50
P577
2013-03-25T00:00:00Z